Congenital nephrogenic diabetes insipidus treated with acetazolamide.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Du Plessis W;Du Plessis W; Chothia MY; Chothia MY
  • Source:
    Nephrology (Carlton, Vic.) [Nephrology (Carlton)] 2024 Jul; Vol. 29 (7), pp. 438-441. Date of Electronic Publication: 2024 Mar 07.
  • Publication Type:
    Case Reports; Journal Article
  • Language:
    English
  • Additional Information
    • Source:
      Publisher: Blackwell Science Country of Publication: Australia NLM ID: 9615568 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1440-1797 (Electronic) Linking ISSN: 13205358 NLM ISO Abbreviation: Nephrology (Carlton) Subsets: MEDLINE
    • Publication Information:
      Original Publication: Carlton, Vic., Australia : Blackwell Science,
    • Subject Terms:
      Diabetes Insipidus, Nephrogenic*/diagnosis ; Diabetes Insipidus, Nephrogenic*/drug therapy ; Acetazolamide*/therapeutic use; Humans ; Male ; Adolescent ; Treatment Outcome
    • Abstract:
      Congenital nephrogenic diabetes insipidus (CNDI) is a rare disorder. The condition is characterised by an inability of distal nephron segments to respond to normal or raised concentrations of serum antidiuretic hormone. In this report, we describe the case of a 13-year-old male known with CNDI who experienced a pedestrian vehicle accident leading to coma following a head injury. Intra-operatively, severe hypernatraemia and polyuria were observed. Following an inadequate response to conventional therapy, acetazolamide was prescribed resulting in an immediate response to therapy. To the best of our knowledge, acetazolamide has not been previously documented as a therapeutic option for CNDI. Additional research is necessary before considering the recommendation of acetazolamide for cases of NDI that do not respond adequately to conventional treatments.
      (© 2024 The Authors. Nephrology published by John Wiley & Sons Australia, Ltd on behalf of Asian Pacific Society of Nephrology.)
    • References:
      Arthus M‐F, Lonergan M, Crumley JM, et al. Report of 33 novel AVPR2 mutations and analysis of 117 families with X‐linked nephrogenic diabetes insipidus. J Am Soc Nephrol. 2000;11:1044‐1054.
      Duicu C, Pitea AM, Săsăran OM, Cozea I, Man L, Bănescu C. Nephrogenic diabetes insipidus in children. Exp Ther Med. 2021;22:1‐6.
      Milano S, Carmosino M, Gerbino A, Svelto M, Procino G. Hereditary nephrogenic diabetes insipidus: pathophysiology and possible treatment. An Update. Int J Mol Sci. 2017;18:2385.
      Halperin M, Kamel K. Hypokalemia. Fluid, Electrolyte, and Acid‐Base Physiology: a Problem‐Based Approach. Saunders. Elsevier; 2017.
      Asim M, Alkadi MM, Asim H, Ghaffar A. Dehydration and volume depletion: how to handle the misconceptions. World J Nephrol. 2019;8:23‐32.
      Chothia M‐Y, George K, Sheik M, Davids MR. Hypodipsic‐hypernatremia syndrome in an adult with polycythemia: a case report. J Med Case Reports. 2018;12:1‐6.
      Bankir L, Bichet DG, Morgenthaler NG. Vasopressin: physiology, assessment and osmosensation. J Intern Med. 2017;282:284‐297.
      Bendz H, Aurell M. Drug‐induced diabetes insipidus: incidence, prevention and management. Drug Saf. 1999;21:449‐456.
      Stasior D, Kikeri D, Duel B, Seifter J. Nephrogenic diabetes insipidus responsive to indomethacin plus dDAVP. N Engl J Med. 1991;324:850‐851.
      D'Alessandri‐Silva C, Carpenter M, Ayoob R, et al. Diagnosis, treatment, and outcomes in children with congenital nephrogenic diabetes insipidus: a pediatric nephrology research consortium study. Front Pediatr. 2020;7:550.
      Allen HM, Jackson RL, Winchester MD, Deck LV, Allon M. Indomethacin in the treatment of lithium‐induced nephrogenic diabetes insipidus. Arch Intern Med. 1989;149:1123‐1126.
      de Groot T, Sinke AP, Kortenoeven ML, et al. Acetazolamide attenuates lithium–induced nephrogenic diabetes insipidus. J Am Soc Nephrol. 2016;27:2082‐2091.
      Kassamali R, Sica DA. Acetazolamide: a forgotten diuretic agent. Cardiol Rev. 2011;19:276‐278.
      Taki K, Oogushi K, Hirahara K, Gai X, Nagashima F, Tozuka K. Preferential acetazolamide‐induced vasodilation based on vessel size and organ: confirmation of peripheral vasodilation with use of colored microspheres. Angiology. 2001;52:483‐488.
      Gordon CE, Vantzelfde S, Francis JM. Acetazolamide in lithium‐induced nephrogenic diabetes insipidus. N Engl J Med. 2016;375:2008‐2009.
    • Contributed Indexing:
      Keywords: acetazolamide; congenital; diabetes insipidus; nephrogenic
    • Accession Number:
      O3FX965V0I (Acetazolamide)
    • Publication Date:
      Date Created: 20240307 Date Completed: 20240626 Latest Revision: 20240626
    • Publication Date:
      20240626
    • Accession Number:
      10.1111/nep.14291
    • Accession Number:
      38450903